Bruce Bode, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1841297751
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,045,323 of the $1,533,148 with a category attached, or 68.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2019 at $386,078 and has fallen 96.3% since, to $14,398 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,837 payments — averaging $540.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$327K
- Novo Nordisk$320K
- Sanofi-aventis U.S. LLC$208K
- Medtronic$107K
- Mannkind Corporation$90K
- Xeris Pharmaceuticals, Inc.$90K
- plus $391K from 54 others
Across 1,893 payments — averaging $8922.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$4.8M
- Abbott$3.1M
- Eli Lilly$2.4M
- Senseonics, Incorporated$2.3M
- Dexcom, Inc.$2.3M
- Insulet Corporation$1.3M
- plus $744K from 9 others
What the payments were for
- Royalty or licence$40,0003%
- Consulting fees$208,12514%
- Speaking & faculty fees$1,045,32368%
- Travel & lodging$183,86412%
- Food & beverage$55,6304%
- Education$2060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$112,959
- SOLIQUA 100/33$99,820
- RYBELSUS$91,810
- AFREZZA$87,272
- GVOKE PFS$80,059
- Eversense$75,981
- TZIELD$65,720
- JARDIANCE$63,646
- LYUMJEV$55,453
- TOUJEO$54,693
- Tresiba$46,090
- InPen$40,843
- FARXIGA$38,757
- MOUNJARO$30,493
- INVOKANA$25,486
- MINIMED 770G$17,222
- Minimed 670G System$15,959
- CeQur Simplicity$15,623
- FreeStyle Libre 2$9,244
- MINIMED 780G$8,640
How this compares
$1,533,148 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 313 | $470,197 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 91 | $128,419 |
| MounjaroTirzepatide | 68 | $117,391 |
| JardianceEmpagliflozin | 87 | $89,630 |
| Tresiba Flextouch U-100Insulin Degludec | 132 | $61,713 |
| FarxigaDapagliflozin Propanediol | 50 | $59,350 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $47,826 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $41,405 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 42 | $39,771 |
| JanuviaSitagliptin Phosphate | 37 | $38,673 |
| FiaspInsulin Aspart (Niacinamide) | 20 | $37,589 |
| TrulicityDulaglutide | 18 | $32,516 |
| HumalogInsulin Lispro | 90 | $29,350 |
| NovologInsulin Aspart | 82 | $28,809 |
| EliquisApixaban | 27 | $28,531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $320,165 | $536,595415 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $327,084 | $183,052208 claims |
| Boehringer IngelheimJardiance, Tradjenta | $26,033 | $98,070101 claims |
| AstraZenecaFarxiga | $29,277 | $59,35050 claims |
| MerckJanuvia, Janumet | $254 | $58,05949 claims |
| PfizerEliquis | $7,608 | $28,53127 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $208,294 | $27,77118 claims |
| AbbVieSynthroid | $433 | $5,86484 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $518 | $2,284186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
- Era ShahAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.